Europe Leber Congenital Amaurosis Market – Industry Trends and Forecast to 2029

 Market Analysis and Insights

Europe leber congenital amaurosis market is driven by the factors such as an increase in the prevalence of chronic diseases such as diabetes & gastrointestinal disorders, a growing number of the up-coming players and the popularity of infusion pumps in-home care services, which enhance its demand, as well as increasing investment in research and development, leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative leber congenital amaurosis treatments and therapies, which is expected to provide various other opportunities in the leber congenital amaurosis market. However, the strict government regulations on approval and device errors during infusion therapy are expected to hamper the growth.

Europe leber congenital amaurosis market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers that propelled the market's demand in the forecast period.

Europe leber congenital amaurosis market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Europe leber congenital amaurosis market will grow at a CAGR of 5.8% during the forecast period of 2022 to 2029.

Europe Leber Congenital Amaurosis Market Dynamics

Drivers

• Increase in treatment-seeking rate

Inherited retinal dystrophies (IRDs) represent a genetically diverse group of progressive, visually debilitating diseases. Adult and pediatric patients with vision loss due to IRD caused by biallelic mutations in the 65-kDa retinal pigment epithelium (RPE65) gene are often clinically diagnosed as retinitis pigmentosa (RP), and leber congenital amaurosis (LCA).

The treatment-seeking individuals related to the disease are the major factor that will generate the demand in the market and act as an opportunity for a particular market. In December 2017, the FDA approved the first-ever retinal gene therapy for the treatment of leber’s Congenital Amaurosis caused by mutations in the RPE65 gene, after which the treatment by the drug went on the rising. Various non-profitable organizations are trying to create initiatives to increase the treatment for the disease.

The growing product launches, private eye care centers, and government strategies have increased the treatment-seeking rate, which is expected to boost the market in the forecasted period and act as an opportunity for market growth.

• Increase in pipeline products and clinical trials

The continuous innovation for the treatment of inherited retinal diseases and leber congenital amaurosis disorder can positively impact the market as the size of the market will increase, when these products are approved in the Europe market. Due to no pharmacological treatments for the LCA, major market players are continuously innovating the treatment or investing in the R&D for the treatment. Various ongoing clinical trials are recruiting worldwide to find the mechanism of diseases for treatment.

Opportunities

•  Increase in government initiatives toward leber congenital amaurosis

According to WHO, the prevalence of monogenic IRDs affects about 1 in 40,000 newborns in Europe. To prevent these, the government of several countries globally have taken initiatives.

The various programs and decisions taken by the government worldwide for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Europe leber congenital amaurosis market.

Restraints/Challenges

• High costs associated with procedure and treatment

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost. The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. The utilization of critical care and intensive care unit services is increasing worldwide, and their expensive cost is a major concern in the current healthcare system.

Patients with a genetic disorder are commonly required to have long treatment with frequent monetarization and other usage, consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis, which demands additional healthcare resources and treatment.

The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

The hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with leber congenital amaurosis treatment and diagnosis is expected to restrain the leber congenital amaurosis market growth.

Recent Developments

• In January 2022, CENTOGENE N.V. announced the global release of CentoCloud, a SaaS platform enabling decentralized analysis, interpretation, and reporting of genomic variants linked to rare diseases. This will help in increasing the product portfolio for rare diseases.
• In July 2017, Spark Therapeutics, Inc submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for LUXTURNA, the proposed trade name for voretigene neparvovec. This has increased company’s revenue and product portfolio.

Europe Leber Congenital Amaurosis Market Segmentation

Europe leber congenital amaurosis market is categorized into disease type, type, end-user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Disease Type

• Infantile Type
• Juvenile Type
• Others

On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others

Type

• Diagnosis
• Therapy

On the basis by type, the leber congenital amaurosis market is segmented into diagnosis and therapy. Diagnosis segment is further segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further segmented into clinical eye examination, visual field test, retail imaging, and electro physiological tests. Clinical diagnosis is sub-segmented into electrophysiological tests, retinal imaging, visual field test and clinical eye examination. Electrophysiology tests is subsegmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Retinal imaging is subsegmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO) and adaptive optics (AO) imaging and conventional color fundus imaging. Visual field tests is sub-segmented into computerized visual field tests and manual field test. Clinical examination is sub-segmented into slit lamp, indirect ophthalmoscopy, refraction test and dilation exam. Therapy segment is further segmented into gene therapy, retinal therapy, neuroprotective agents, and others. Gene therapy is further segmented into luxturna and others. Neuroprotective agents are further segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, and others.

End User

• Hospitals
• Specialty clinics
• Ambulatory surgical centers
• Home healthcare
• Others

On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.

Distribution Channel

• Retail Sales
• Direct Tender

On the basis of distribution channel, the leber congenital amaurosis market is segmented into retail sales, direct tender.

Leber Congenital Amaurosis Market Regional Analysis/Insights

The leber congenital amaurosis market is analyzed and market size insights and trends are provided by country, disease type, type, end user, and distribution channel as referenced above.

The countries covered in the leber congenital amaurosis market report are the Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe.

In Europe, Germany is expected to dominate due to increasing incidence and prevalence of rpe65 gene-mediated in retinal diseases.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Leber Congenital Amaurosis Market Share Analysis

Europe leber congenital amaurosis market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies' focus on the leber congenital amaurosis market.

Some of the major players in the market are Invitae Corporation, Spark Therapeutics, Inc., CENTOGENE N.V., Allergan, Novartis AG, among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-68123